GM-SR1 Tablet contains a combination of Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which aids in lowering blood glucose levels. The synergistic effect of these two agents helps achieve better glycemic control in patients inadequately controlled on diet and exercise alone or on monotherapy. GM-SR1 Tablet is typically prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. It is important to use this medication under medical supervision to minimize risks such as hypoglycemia, lactic acidosis, and gastrointestinal disturbances. Dose adjustments may be necessary based on renal function and glycemic response. Patients should be advised to adhere to prescribed dosing schedules and report any adverse effects promptly. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended to ensure safety and efficacy during treatment with GM-SR1 Tablet.